HIGHLIGHTS
- who: Andrea Napolitano and colleagues from the Department of Medical Oncology, Università Campus Bio-Medico, Rome, Italy have published the research: Recent Advances in Desmoid Tumor Therapy, in the Journal: Cancers 2020, 2135 of /2020/
- what: The study showed a 6-month disease control rate of 83.7% for the pazopanib group and 45.0% for the methotrexate-vinblastine group with an objective response rate of 37% and 55%, respectively .
- future: Ongoing Trials and Future Directions Several trials investigating novel targeted therapies in advanced unresectable DT are currently ongoing based on the better . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.